Track topics on Twitter Track topics that are important to you
Bicycle Therapeutics, Cambridge-based British biotech firm, has announced that it has signed a deal that could potentially be worth over $1 billion with AstraZeneca. The deal will see Bicycle identify an undisclosed number of bicyclic peptides for AstraZeneca which can then further develop the targets.
Original Article: AstraZeneca inks $1 billion deal with Bicycle TherapeuticsNEXT ARTICLE
Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...
AstraZeneca is ranked 6th in the world, based on a pharmaceutical annual sales, which were valued at $32,800 million in 2009. it is a global company, working in more than 100 countries, and employing 62,000 people, around a sixth of which are dedic...